Market Overview:
A vector is a tool for delivering genetic material into cells. The modified viral vector is used as the viral vector in gene therapy. Plasmid D viralNA is a bacterial smaller, circular and extrachromosomal DNA used in different molecular genetic research such as gene therapy, gene transfer, and recombinant DNA technology due to its self-replication property. A gene of interest is transferred into the target cell for studying the function or expression of a gene.
Market Size Growth Rate:
According to the research report published by the DataM Intelligence, the North America viral vector and plasmid DNA manufacturing market size was valued at USD billion in 2021, it is projected to reach USD billion by 2029, with growth at a CAGR over the forecast period 2022-2029.
There is an increasing number of clinical studies conducted on viral vector manufacturing, emphasizing the potential of gene therapy to address important medical needs. Major pharmaceutical companies such as AstraZeneca, and Janssen Pharmaceuticals have developed COVID-19 viral vector-based vaccines in December 2020 and February 2021, respectively. Apart from these companies, several viral vector-based vaccines are currently in the development phase. This has accelerated the demand for viral vectors, thereby increasing revenue for viral vector manufacturers.
Market Drivers:
The market is driven by the increasing demand for viral vectors and plasmid DNA manufacturing for developing DNA vaccines, gene therapy, immunotherapy, and others. There is growing usage of the viral vectors & plasmid DNA due to their advantages such as high transfection efficiency, effective gene delivery, and stable gene expression. There is a rise in the number of clinical studies for examining the efficacy and safety of the viral vectors. In addition, increase in the launch of the contract manufacturing business for viral vectors and plasmid DNA manufacturing. For instance, in December 2019, Helixmith Co., Ltd. and Genopis launched the contract manufacturing business for plasmid DNA production.
Market Restraints:
However, some of the limitations of gene therapy is likely to hamper the market growth. In addition, risk associated with viral vectors, complex and expensive manufacturing processes, and regulatory challenges are some of the restraints to the market growth.
Market Opportunities
The success of any viral-vector manufacturing market depends on its ability to get past multiple lines of defense deployed by the human immune system. Viral capsids, viral-vector DNA, and even the transgene products themselves may be recognized as foreign, providing multiple opportunities for the immune system to clear the gene therapy from the body. In addition, the COVID-19 pandemic and the R&D for vaccines have created serval opportunities for the market.
COVID-19 Impact Analysis
The COVID-19 pandemic has underlined the importance of vaccine development for the global population. According to the World Health Organization (WHO), around 151 vaccine candidates have been subjected to preclinical studies and 42 vaccines have reached clinical trials. Viral vectors have played a central role, especially using adenovirus-based vectors. Additionally, other viral vectors based on vaccinia viruses, measles viruses, rhabdoviruses, influenza viruses, and lentiviruses have been subjected to vaccine development. Increasing research involving viral vectors is expected to continue at least for the next one or two years. This is expected to boost the market growth.
Download Sample Brochure @ https://www.datamintelligence.com/download-sample/north-america-viral-vector-and-plasmid-dna-manufacturing-market
Recent Developments in the Industry:
Market Segmentation:
As per the research analysis, the viral vector and plasmid DNA manufacturing market is segmented by type into retroviral vectors, adenoviral vectors, lentiviral vectors, adeno-associated viral vectors, and others. Based on disease, the market is segmented into cancer, genetic disorder, infectious disease, and other diseases. Further, by application, it is further divided into gene therapy, and vaccinology, and by end-user, it is segmented into pharmaceutical and biopharmaceutical companies, and research institutes.
Geographical Classification:
The North American viral vector and plasmid DNA manufacturing market is segmented into major countries including the US, Canada, and Mexico.
US Viral Vector And Plasmid DNA Manufacturing Market:
In the North American region, the United States holds the dominant share of about 71% in 2020, followed by Canada. The United States is the most lucrative market for viral vector and plasmid DNA manufacturing. The growth in the region is due to the presence of several biopharmaceutical manufacturers in the U.S., coupled with advanced funding and public awareness. The Alliance for Regenerative Medicine (ARM), a U.S.-based non-profit organization in the field of gene therapy, reported a 164% increase in funding for gene and gene-modified cell therapy in 2017 over 2016 and a global investment of USD 4.5 billion in 2017. In November 2018, the National Institutes of Health (NIH) launched a new initiative to accelerate the adoption of gene therapy to cure around 20 million patients diagnosed with sickle cell disease.
Competitive Analysis:
Companies involved in the development of vector agent-based products often seek support from contract service providers for the launch of clinical-grade products. This is primarily because of the complexity and limited availability of technologies and platforms used for vector designing, production, packaging, and release testing. The major players are entering into collaborations, acquisitions, mergers, and licensing activities for increasing their market presence. For instance, in January 2021, Thermo Fisher Scientific acquired the viral-vector manufacturing business of the French pharmaceutical services firm Novasep for approximately $875 million.
Make an inquiry to purchase the complete study @ https://www.datamintelligence.com/enquiry/north-america-viral-vector-and-plasmid-dna-manufacturing-market
Major Companies:
Lonza, Merck, Oxford BioMedica, CGT Catapult, Cobra Biologics, UniQure, Sanofi, FUJIFILM Diosynth Biotechnologies, Cobra Biologics, Thermo Fisher Scientific, Inc., and Spark Therapeutics are some of the major key players in the market.
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query with regards to the scope offered will be addressed within 24- 48 hours.
3) An excel sheet with market numbers will be provided separately.
The Full Report has the below insights:
Media ContactCompany Name: DataM IntelligenceContact Person: SaiEmail: Send EmailPhone: +1 877 441 4866Country: United StatesWebsite: https://www.datamintelligence.com/research-report/north-america-viral-vector-and-plasmid-dna-manufacturing-market